A Common Nutrient Could Supercharge Cancer Treatment
University of Chicago researchers found that the dietary carotenoid zeaxanthin directly boosts CD8⁺ T‑cell activity, enhancing the immune system's ability to recognize and destroy cancer cells. In mouse models, dietary zeaxanthin slowed tumor growth and amplified the effects of checkpoint‑inhibitor immunotherapy. Laboratory tests also showed that zeaxanthin improves the killing efficiency of engineered T cells against melanoma, multiple myeloma and glioblastoma. Because zeaxanthin is an inexpensive, over‑the‑counter supplement, it could be rapidly evaluated as a low‑cost adjunct to existing cancer treatments.
Vutrisiran Cuts Risk of Advanced ATTR-CM, Improves Outcomes in Those Who Progress
Vutrisiran (Amvuttra) demonstrated in the phase 3 HELIOS‑B trial that it slows progression to advanced heart failure in transthyretin amyloid cardiomyopathy (ATTR‑CM), with 8.0% of treated patients reaching advanced disease versus 10.7% on placebo. Among the 61 patients who did progress,...
Emerging Therapies Bring Hope for Frail HNSCC Patients Unfit for Standard Treatment
Head and neck squamous cell carcinoma (HNSCC) cases are projected to rise to 273,000 by 2034, with frail and elderly patients expected to comprise 44% of the market. Standard curative regimens are often intolerable for this group, creating a sizable...
TEFCA Can Enable Patient-Centered Data Exchange
University of Iowa Health Care’s Josh Wilda highlighted that the Trusted Exchange Framework and Common Agreement (TEFCA) could go beyond provider‑to‑provider connectivity to unify the nation’s fragmented patient portals. By establishing a single, standards‑based access point, patients would retrieve their...
Opinion: For AI to Have Impact, the Industry Must Align on Data
Artificial intelligence is now embedded across biopharmaceutical R&D, highlighted by the FDA's adoption of the generative tool Elsa for drug‑approval reviews. Industry leaders, including Charles River Laboratories, warn that AI's promise hinges on the quality, metadata, and harmonization of the...
'How Are You Using AI?' Your Therapist Should Ask You that Question, Experts Argue
A new JAMA Psychiatry paper urges therapists to ask patients about AI chatbot use for emotional support. Researchers argue AI interactions can reveal hidden stressors, coping strategies, and even suicidal ideation, offering a “treasure trove” of clinical data. The authors...
Exploring TEFCA's Potential to Empower Rural Providers
University of Iowa Health Care’s AVP for information systems, Josh Wilda, highlighted that connecting to the Trusted Exchange Framework and Common Agreement (TEFCA) can enable rural Iowa clinics with limited IT resources to share patient data seamlessly. TEFCA’s standardized network...
Know Your Patient: How Technology Can Help Health Care Providers Dramatically Improve One Key Aspect of the Patient Experience
The article argues that AI can close the biggest gap in patient experience—feeling understood—by automating note summarization and turning wearable data into actionable insights. It notes that simple digitization of records has not reduced clinician workload, leaving patients frustrated and...
Healthcare’s Most Fixable Cost Problem: Administrative Waste
Healthcare administrative costs are spiraling, with urban hospital admin expenses up more than 90% between 2011 and 2022 while overall hospital services grew 66%. Premiums for employer‑sponsored plans are already 10% higher this year, and the burden on employers is...
Could Intuitive Surgical Be a Trillion-Dollar Company?
Intuitive Surgical (ISRG) sits at the center of a $4 trillion global surgery market, driven by an estimated 425 million unmet procedures worldwide. While the total addressable market for all surgeries is massive, only about 5 %—roughly 20 million cases—are suitable for robotic, minimally...
Revvity Unveils Its Signals BioDesign Offering
Revvity Signals Software introduced Signals BioDesign, a cloud‑native molecular cloning platform aimed at biotech and pharma R&D teams. The solution consolidates Golden Gate, Gibson assembly, restriction/ligation, primer design, and sequencing analysis, supporting up to 1,000 constructs per project. Integrated with...
Protecting Access to Care for Our Most Severely Ill Patients
Long‑term care hospitals (LTCHs) deliver intensive, extended treatment for the most severely ill Medicare beneficiaries. Since the 2016 dual‑rate payment system, Medicare reimbursements to LTCHs have dropped roughly 45%, contributing to a 25% decline in operating LTCHs over the past...
Exploring the Value of Quality Peptide Supplies
Peptide research has surged, making high‑purity synthetic peptides essential for reliable experiments. Quality hinges on ≥98% purity verified by HPLC, accurate molecular weight confirmed by mass spectrometry, and proper lyophilization with cold‑chain logistics. The article outlines a supplier checklist—third‑party testing,...
Senju Launches First-in-Class Dry Eye Disease Drug in Japan
Senju Pharma has launched Avarept, the first TRPV1 antagonist drug for dry eye disease (DED) in Japan, licensed from Mochida and distributed by Takeda. The ophthalmic suspension is priced at ¥577.50 (approximately $3.63) per 5 ml bottle. DED affects over 20 million...
Pharmaceutical Tariffs and the Restructuring of Global Drug Supply Chains
The United States is rolling out new tariffs on imported pharmaceutical products, affecting an estimated $200‑$250 billion in annual trade. Because 70‑80% of active pharmaceutical ingredient (API) production is concentrated in India and China, manufacturers face limited flexibility and longer lead...
From Unused Data to Improved Experiences - How Trillium Health Partners Put Patient Voices to Work with Qualtrics
Trillium Health Partners in Mississauga replaced paper‑based patient surveys with Qualtrics’ digital platform, enabling feedback delivery within 24 hours of discharge. The real‑time insight allows unit managers to see complaints and compliments within days, turning stale data into actionable improvement. By...
Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-Cell Engagers for Solid Tumors
Oxford BioTherapeutics (OBT) announced a multi‑year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next‑generation T‑cell engager therapies for solid tumors. OBT will apply its OGAP‑Verify platform to identify tumor‑selective antigens and design candidate molecules, while BMS...
The Healthcare Burnout Backlash (Pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
The third installment of MedTech Intelligence’s burnout series argues that staffing shortages are symptoms of outdated, siloed workflows rather than pure labor deficits. Healthcare leaders are turning to targeted workflow redesign—especially in patient access, revenue cycle and EHR processes—to eliminate...
BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
BD announced that its Liverty TIPS Stent Graft has received CE Mark approval, allowing sales across the European Union. The next‑generation device features an adjustable 6–10 mm inner diameter and the longest range of covered TIPS stent lengths, aimed at personalizing...
Oricell Therapeutics Raises $110 Million to Advance Global Cell Therapy Development
Oricell Therapeutics announced a $110 million pre‑IPO financing round aimed at accelerating its global cell‑therapy program. The capital will fund expanded clinical trials, manufacturing upgrades, and a broader market rollout, especially for its lead liver‑cancer therapy that is nearing pivotal studies....
Endospan Receives FDA Approval for the NEXUS Aortic Arch Stent Graft System
Endospan announced FDA approval of its NEXUS Aortic Arch Stent Graft System, clearing the way for a U.S. commercial launch. The clearance was based on one‑year results from the TRIOMPHE IDE study, which demonstrated safe and effective treatment of high‑risk...
Scientists Uncover the Neurological Mechanisms Behind Cannabis-Induced “Munchies”
A University of Calgary team published a study in PNAS showing that inhaled THC vapor triggers a robust, short‑lived increase in food consumption in both humans and rats. In a controlled trial with 82 volunteers, any dose of cannabis vapor...
Apr 10 Policy Watch: HHS Updates Criteria for Selecting Vaccine-Committee Members
The U.S. Health and Human Services Department renewed the Advisory Committee on Immunization Practices charter, shifting from professional‑society representation to a broader, geographically and specialty‑balanced membership. The EPA finalized a rule extending permissible natural‑gas flaring to 72 hours and easing...
Slidell Doctor Sentenced For $6.6 Million In Health Care Fraud
Robert Tassin, a 67‑year‑old physician from Slidell, Louisiana, was sentenced on April 9, 2026 for conspiring to commit healthcare fraud by ordering medically unnecessary cancer genetic tests for Medicare patients he never saw. The scheme generated over $6.6 million in false claims, of...
NIH Awards Fewer Grants Despite Increased Funding, Raising Concerns over Research Delays
Despite a recent federal funding boost, the National Institutes of Health has awarded only about 30% of the new research grants it typically funds this fiscal year. Delays in fund disbursement, driven by Office of Management and Budget restrictions, have...
Will RFK Jr.’s Peptide Push Bolster the Gray Market for Obesity Drugs?
Robert F. Kennedy Jr. is urging the FDA to reclassify more than a dozen synthetic peptides from the restricted Category 2 list to Category 1, allowing compounding by licensed pharmacies with a prescription. The move follows a high‑profile appearance on the Joe...
Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma
Biotech IPO activity is resurging, highlighted by Evommune’s public listing and a panel at the BIO International Convention discussing renewed exit opportunities. AI-driven collaborations, such as Insilico Medicine and Aska Pharmaceutical, aim to tackle unmet needs in women’s health by...
Re: Make Compassion Visible in Emergency Medicine Again
In a response to Iain Beardsell’s article, emergency‑medicine consultant Chris Turner argues that the profession’s growing systemic strain has dulled compassion, turning clinicians into inadvertent partners in a failing system. He cites moral injury from the shift between risk mitigation...
Orthanc DICOM Vulnerabilities Lead to Crashes, RCE
A CERT/CC advisory disclosed nine critical vulnerabilities (CVE‑2026‑5437 to CVE‑2026‑5445) in the open‑source Orthanc DICOM server, affecting versions up to 1.12.10. The flaws include out‑of‑bounds reads, decompression‑bombs, memory‑exhaustion bugs, and heap buffer overflows that can crash servers, leak image data,...
InVera Medical Receives FDA Clearance for Non-Thermal Chronic Venous Disease Device
InVera Medical secured FDA 510(k) clearance for its InVera Infusion Device, a 5Fr catheter with a helical coil designed to improve sclerotherapy delivery for chronic venous disease (CVD). The non‑thermal, minimally invasive tool prepares the vein wall mechanically, allowing a...
Diagnostics Lag Is Holding Back New Therapies, Says Study
A new UCSF analysis published in Science warns that diagnostic development is lagging behind therapeutic breakthroughs because of regulatory and reimbursement gaps. The authors highlight that nearly half of the world’s population—about 47%—has limited or no access to essential tests,...
Senkyunolides: A Promising Natural Compounds for the Treatment of Migraine Headaches
A Frontiers in Nutrition review published April 10, 2026 examines senkyunolides—phthalide‑type compounds from herbs such as Ligusticum chuanxiong—as a new class of natural anti‑migraine agents. The authors detail the compounds’ chemical diversity, modern extraction and purification methods, and multi‑target mechanisms that modulate...
The Preoperative Albumin-to-Carcinoembryonic Antigen Ratio (ACR) Predicts Prognosis and Facilitates Risk Stratification in Gastric Cancer: A Retrospective Cohort Study
The retrospective cohort of 1,161 gastric‑cancer patients who underwent radical gastrectomy showed that a low pre‑operative albumin‑to‑CEA ratio (ACR) correlates with aggressive pathology and significantly shorter overall and disease‑free survival. Multivariate Cox analysis identified high ACR as an independent protective...
The Effect of Immunonutrition on Postoperative Ileus Following Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
A systematic review and meta‑analysis of 28 randomized trials involving 2,367 colorectal cancer patients found that peri‑operative immunonutrition significantly accelerates gastrointestinal recovery. Compared with standard diet, immunonutrition reduced time to first flatus by 0.56 days, time to first defecation by...
DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer
DualityBio announced that China’s National Medical Products Administration has accepted its Biologics License Application for trastuzumab pamirtecan (T‑Pam), an investigational antibody‑drug conjugate targeting HER2‑positive metastatic breast cancer. The submission is backed by interim data from the pivotal Phase III DB‑1303‑O‑3001 trial,...
FDA Probes Abortion Pill Anew After Court Keeps Mail Access Alive
The FDA announced a renewed, accelerated safety study of the abortion pill mifepristone, aiming to complete the review faster than typical academic timelines. The move follows a Louisiana federal judge’s decision to temporarily allow the drug’s distribution by mail while...
Novo's Double Departures: As GLP-1 Luminary Retires, an Obesity Leader Goes to Boehringer Ingelheim
Novo Nordisk announced two high‑profile departures this week. Lotte Bjerre Knudsen, a veteran who helped launch the company’s breakthrough GLP‑1 therapies, is retiring after more than two decades. At the same time, the head of Novo’s obesity unit has accepted a...
Ind. FD Launches Program to Divert Non-Emergency 911 Calls to Nurses
The Terre Haute Fire Department (THFD) has launched the Crosswalk to Care program to divert low‑acuity 911 calls to registered nurses for appropriate care navigation. Over the past seven years, THFD’s run calls grew by 450 annually, with roughly 20%—about...
Chinese Trial Backs Base-Editing Drug for Thalassaemia
A Chinese investigator‑led trial of CorrectSequence Therapeutics' ex vivo base‑editing drug CS‑101 showed that all five patients with transfusion‑dependent beta‑thalassaemia became transfusion‑independent after a single infusion, with an average cessation time of 16 days and sustained hemoglobin gains over three months....
Sobi Reports Health Canada Approval of Empaveli for C3G and Primary IC-MPGN
Health Canada has granted approval for Empaveli (pegcetacoplan) to treat patients aged 12 and older with C3 glomerulopathy (C3G) or primary immune‑complex membranoproliferative glomerulonephritis (IC‑MPGN). The decision follows the Phase III VALIANT trial, which demonstrated a 68% reduction in proteinuria, stabilization...
America’s Healthcare Innovation Problem
The article argues that U.S. healthcare innovation suffers from a culture that declares success too early and hides failure, using examples from Medicare Advantage and the Theranos scandal. It highlights how funding, valuations, and hype often replace rigorous outcome evaluation,...
Sumeet SSG Partners Pinnacle Industries to Strengthen Maharashtra’s EMS Fleet
Sumeet SSG BVG Maharashtra EMS has teamed up with Pinnacle Industries to build a new fleet of ambulances for the state’s Emergency Medical Services (MEMS 108) project. The partnership will deliver 1,756 Advanced Life Support, Basic Life Support and neonatal ambulances...
No One Knows Where US Vaccine Policy Goes Next
Health and Human Services Secretary Robert F. Kennedy Jr. has stalled his sweeping vaccine overhaul after a federal judge invalidated the newly appointed ACIP members and blocked changes to the childhood immunization schedule. Kennedy’s earlier moves—dropping Covid‑19 recommendations for healthy...
CDC Testing Pause Puts Clinical Labs at the Center of Public Health Response
The Centers for Disease Control and Prevention has temporarily halted testing for several infectious diseases, including rabies, poxviruses, certain parasites, and lymphocytic choriomeningitis. The pause, framed as a routine quality‑assurance review that began in 2024, is expected to last a...
Surface‑Engineered Primer Immobilization Enables Simplified and Affordable Nucleic‑Acid Capture for Molecular Diagnostics in Sub‑Saharan Africa
A study introduces a silica‑free nucleic‑acid capture method using polycarbonate surfaces modified with acetone‑UV pretreatment and branched polyethyleneimine linkers. The treatment doubles surface carboxyl groups, and BPEI chemistry attaches about 2.6 times more primers than conventional ethylenediamine links. Fluorescence assays confirm...
Understanding the Role of Oral Surgery in Overall Health
Oral surgery is increasingly recognized as a preventive and restorative tool that safeguards overall health, not just a remedy for complex dental problems. Untreated oral infections can seed bacteria into the bloodstream, triggering systemic inflammation and taxing the immune system....
Watch: As AI Makes More Health Coverage Decisions, the Risks to Patients Grow
Health insurers are touting artificial intelligence as a cost‑saving tool for coverage decisions, a claim echoed in recent earnings calls. The Trump administration has launched a pilot using AI to streamline Medicare prior‑authorization, signaling federal support for algorithmic triage. However,...
Assessing Bias and Precision in State Policy Evaluations
The study used state‑level opioid overdose deaths (1999‑2016) to test seven panel‑data estimators under four time‑varying policy scenarios. Simulations revealed that augmented synthetic control reduced bias but raised variance when effects waned, while difference‑in‑differences struggled with non‑monotonic impacts and autoregressive...
For Many Patients Leaving the ICU, the Struggle Has Only Just Begun
The article highlights post‑intensive care syndrome (PICS), a cluster of lasting physical, cognitive, and mental health problems that affect more than half of the roughly 5 million Americans admitted to ICUs each year. It follows the recovery of Joseph Masterson, who...
AllRock Bio Begins Patient Dosing in Phase IIa ROCSTAR Trial
AllRock Bio has begun dosing the first patients in its Phase IIa ROCSTAR trial of ROC‑101, an oral pan‑ROCK inhibitor aimed at pulmonary hypertension. The multi‑center study will enroll up to 30 pulmonary arterial hypertension (PAH) patients and 10 interstitial lung...